NEWSROOM Press Releases

    254 Results

    The GeneStrat® Liquid Biopsy Test Earns Approval from NY State-CLEP

    The GeneStrat test, a liquid biopsy test used in lung cancer, has earned approval from NY State-CLEP, along with several other demanding certifications.

    Biodesix® and Positive Bioscience Announce Partnership to Bring Cancer Tests to India

    The Positive Bioscience agreement will make GeneStrat and VeriStrat tests available in India

    New Data Show Biodesix’s VeriStrat® Test is Cost-Saving, Improves Survival and Quality of Life in Advanced Lung-Cancer Patients

    VeriStrat test saved an average of $1,050 per patient while improving survival outcomes (as compared to patients treated without the use of the test).

    Lung Cancer: VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy

    Peer reviewed journal: VeriStrat test identifies patients with squamous cell lung cancer who are more likely to have improved survival on afatanib (Gilotrif)

    New Study Shows Advanced Diagnostic Tests, Including the VeriStrat® Test, Can Help Physicians Improve Cancer Care Planning and Reach Quality Measures For Patients

    A new study demonstrates that VeriStrat can help physicians improve quality care and cancer care planning for patients with advanced lung cancer.

    Study Published In Managed Care Regarding Prognostic and Cancer-Care Planning Value of Biodesix’s VeriStrat® Proteomic Test

    A recent study published in the peer-reviewed journal Managed Care affirms VeriStrat; demonstrates the value of the VeriStrat lung cancer test

    Interim Results from Biodesix® Study Indicate That VeriStrat Testing Impacts Treatment Decisions Across All Stages of Non-Small Cell Lung Cancer

    Interim study results: Veristrat testing impacts lung cancer treatment in all stages; early stage patients get significantly different treatments after test

    2018 Preliminary Private Payor Rate-Based Payment Amounts Released for Clinical Diagnostic Laboratory Tests; Biodesix Commends CMS for Committing to On-Time PAMA Implementation

    Biodesix commended the Centers for Medicare & Medicaid Services (CMS) for publishing preliminary 2018 rates for clinical diagnostic laboratory tests.

    Biodesix Presents Cell-free DNA Process Optimization for Liquid Biopsy Test

    Biodesix is presenting two talks on DNA process optimization at the Cancer Genomics Consortium

    Biodesix Presents Data From Three Studies at AACR Annual Meeting

    New Biodesix data on liquid biopsy genomic tests, evaluation of biological processes underlying mass spectrometry proteomic assays of human serum

    1 2 3 4 5 6 7 8 9